Ben Auspitz is a Partner at F-Prime Capital. He has worked in pharmaceuticals and life sciences for over 15 years, both in industry as a consultant and as an investor. Before joining Fidelity, Mr. Auspitz served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly listed company (NASDAQ: CRXX). In this role, he oversaw the advancement of seven programs from assay stage into Phase 2 human clinical studies, and was co-inventor on 15 product patents. Mr. Auspitz serves on the Board of Directors of Bikam Pharmaceuticals, ReGenX Biosciences, and is a Founder and Chairman of the Board of Dimension Therapeutics. Previously, Mr. Auspitz was involved in Fidelity Biosciences investments in Ligocyte Pharmaceuticals (acquired by Takeda) and Respivert (acquired by Johnson & Johnson), and Ultragenyx (NASDAQ: RARE). He holds a B.A.from Harvard University.
Tom Beck, M.D. is an Executive Partner at F-Prime Capital. Most recently, Dr. Beck served as President, Chief Operating Officer at Dyax Corp. Prior to that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc. (Chairman and Chief Executive Officer) and Enzytech Inc. (President). He began his industry career at Smith Kline and French, and held positions in both clinical and business development. Dr. Beck currently serves on the boards of Mersana Therapeutics, Adagene Inc., and Dimension Therapeutics (where he is currently Chief Executive Officer), and is an observer to the boards of Aclaris Inc. and Rugen Therapeutics. Previously, he served on the boards of Neurotherapeutics Pharma, Vicept Inc., and Topaz Inc. (where he also served as Chief Executive Officer). Dr. Beck is board-certified in internal medicine and nephrology and was Assistant Professor of Medicine at Temple University School of Medicine. He received his Bachelor of Science degree from Yale University and his medical degree from Cornell University.
Rishi Gupta, J.D. is a Private Equity Partner at OrbiMed. Previously, he was a healthcare investment banker at Raymond James & Associates and served as Manager of Corporate Development at Veritas Medicine. Mr. Gupta has published scientific articles on the mechanisms of HIV entry into host cells and legal articles on intellectual property laws in the developing world. He received his bachelor’s degree (magna cum laude) in biochemical sciences from Harvard College and holds a law degree from Yale Law School. Rishi currently serves as a director or observer on the boards of Symbiomix, Sientra, Avitide, Arsanis, Alector, DFine, and Dimension Therapeutics, and was involved in OrbiMed’s investments in CoGenesys, Acceleron Pharma, Supernus Pharmaceuticals, Seragon Pharmaceuticals, Aragon Pharmaceuticals, Adimab, Receptos, and ChemoCentryx.
Klaus Veitinger, M.D., Ph.D. is currently a Venture Partner with OrbiMed. During his prior 16-year pharmaceutical career, Dr. Veitinger held senior management positions in drug development, licensing and business development, strategic planning and M&A, as well as general management. Most recently Dr. Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma Inc. with responsibility for the U.S. and Asia businesses culminating in the ultimate sale of the Schwarz Group. Dr. Veitinger has served and currently serves on the boards of several private and public companies in the life sciences sector. For seven years he was a Director of PhRMA. Dr. Veitinger received his medical degree and his doctorate (Ph.D.) from the University of Heidelberg. He earned his M.B.A. at INSEAD in France.
Chandra P. Leo, M.D. is a Partner at HBM Partners. He has gained over ten years of experience in healthcare venture capital at HBM Partners and Wellington Partners. Dr. Leo currently serves as an observer to the board of Symbiomix and as a director on the boards of CardiacAssist, Delenex Therapeutics, Gynesonics and i-Optics. He was previously a board director or observer at Anthera Pharmaceuticals, ChemoCentryx, ESBATech and Panomics. Dr. Leo also worked as a postdoctoral scientist in the Dept. of Obstetrics & Gynecology at Stanford University and as a gynecologist at the University Hospital of Leipzig, Germany. He received his doctoral degree in medicine from the Freie Universitaet Berlin / Charité in Germany and earned his M.B.A. at INSEAD in France.
Karen A. Dawes Ms. Dawes is President and founder of Knowledgeable Decisions, LLC, a pharmaceutical consulting firm focusing on corporate and commercial strategy. Prior to founding Knowledgeable Decisions, Ms. Dawes held senior executive and commercial positions at key biopharmaceutical companies and was responsible for the successful launch and marketing of a such blockbuster drugs as Zoloft, Glucotrol, and Avelox. Ms. Dawes was Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group, Senior Vice President, Global Strategic Marketing for Wyeth, and Chief Commercial Officer for biotech pioneer Genetics Institute. Ms. Dawes began her pharmaceutical career at Pfizer, Inc. where she was most recently Vice President, Marketing for the Pratt Division. Ms. Dawes is Chairperson of the Board of Directors of Repligen Corporation, and serves on the Boards of Depomed, Inc., and Medicines 360. Ms. Dawes received her M.B.A. from Harvard University and her B.A. and M.A. in English and Communications from Simmons College.